Predicting Device Success and Early Clinical Outcome after Transa
Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

+44 7868 792050

Research Article - (2016) Volume 6, Issue 2

Predicting Device Success and Early Clinical Outcome after Transapical Aortic Valve Implantation

Peter Donndorf1*, Andrea Fries1, Änne Glass2, Gustav Steinhoff1 and Alexander Kaminski1
1Department of Cardiac Surgery, University of Rostock, Rostock, Germany, E-mail:
2Institute for Biostatistics and Informatics in Medicine and Ageing Research, University of Rostock, Rostock, Germany, E-mail:
*Corresponding Author: Peter Donndorf, Department of Cardiac Surgery, University of Rostock, Schillingallee 35, 18057 Rostock, Germany, Tel: +49-381494-6101 Email:


Objective: Pre-procedural evaluation of aortic valve patients is based on the prediction of perioperative risk for a conventional aortic valve replacement (AVR) utilizing standardized risk scores. However, in in the era of transcatheter aortic valve implantation (TAVI) the specific prediction of procedural outcome of an interventional approach seems of growing importance. We aimed to isolate patient- and approach-related factors, predicting procedural outcome of transapical aortic valve implantation (TA-TAVI), especially focusing on parameters not included in standard risk scores (e.g. BMI, intracardiac anatomy, preoperative NT-proBNP).
Methods: A cohort of 60 patients suffering from severe aortic stenosis and receiving TA-TAVI at our institution was analyzed (mean age was 77.7 ± 6.3 years, 50% male). All patients exhibited a high risk for conventional AVR (EuroScorelog ≥ 20 or porcelain aorta) and were scheduled for a TA approach using an Edwards Sapien valve following heart-team discussion. Prior the procedure, all patients underwent multi-slice computed tomography examination. In order to evaluate the procedural and clinical outcome after TA-TAVI, three endpoints were defined: More than mild postoperative paravalvular leak (PVL), postoperative mean transvalvular gradient > 14 mmHg and a composite endpoint of 30-day mortality, stroke and myocardial infarction. For isolation of outcome predictors, fourteen different potential predictors were included into primary univariate regression analyses, seven of which entered subsequent multivariate analyses.
Results: A BMI ≥ 30 was found in multivariate logistic regression to double the risk for both more than mild PVL and higher postoperative transvalvular gradients, however without reaching statistical significance (OR 2.57 95% CI 0.69-9.52; p=0.157 and OR 2.32 95% CI 0.57-9.45; p=0.242, respectively). Male gender and COPD were both associated with a decreased risk for elevated postoperative gradients. Of the analyzed approach-related parameters, especially a LVOT-aorta angle <120° was associated with an increased risk of the composite end-point (OR 6.65 95% CI 0.93-47.4; p=0.059). Furthermore preoperative NT-proBNP levels <400 ng/ml were found to predict a trend towards higher postoperative transvalvular gradients (OR 5.15 95% CI 0.32-81.9; p=0.246).
Conclusion: Standardized risk scores for conventional AVR are limited in terms of predicting the early outcome of TAVI procedures. The current study provides evidence that specific parameters such as the LVOT-aorta angle are likely to improve outcome prediction of patients undergoing TAVI procedures.

Keywords: Transapical TAVI; Device success; Outcome; LVOT-aorta angle; Risk scores


For patients suffering from severe aortic valve stenosis, surgical aortic valve replacement is considered the gold-standard and first line therapy [1].

However, since the patient cohort affected by aortic valve stenosis is continuously aging, relevant comorbidities are frequently increasing the risk of a surgical aortic valve replacement (AVR). In order to address this issue of high risk or even non-operable patients, transcatheter aortic valve implantation (TAVI) procedures were developed during the last decade [2] and have been implemented successfully into the therapeutic repertoire for patients suffering from aortic valve stenosis [3]. Until today, feasibility has been proven for both, the antegrade transapical (TA) as well as retrograde (transfemoral (TF), transaortic (TAO) and transsubclavian (TS)) approaches. The main advantages of TAVI procedures include the avoidance of cardiopulomonary bypass and aortic cross clamping as well as the possibility to perform the procedure without general anesthesia in case of a transfemoral approach.

Since long-term results comparable with those available for surgical AVR have not been gathered so far, TAVI is currently restricted to non-operable and surgical high-risk patients [4]. The risk evaluation is based on standardized scoring systems, such as the STS score [5] or the EuroScore [6]. However, both scoring systems have been standardized for conventional surgical procedures and are not validated to predict the procedural outcome and mortality after TAVI. Therefore this kind of procedural allocation based exclusively on surgical risk scores is likely to fall short of valid outcome prediction in case of TAVI.

Furthermore the decision on a TA vs. TF approach, currently representing the two predominant TAVI approaches, is often driven by a rather subjective, non-standardized evaluation of an underlying vascular disease. As there is continuously growing experience on the advantages and drawbacks of either major TAVI approach [7], the process of patient evaluation as well as the overall outcome after TAVI might profit from the application of more specific, patient- and approach-related outcome predictors as primary evaluation parameters. In the current study we therefore aimed at evaluating specific parameters, such as indicators of a difficult intracardiac anatomy as potential outcome predictors in patients undergoing TA-TAVI. In this context data have already been provided for example regarding the impact of total aortic calcification burden on mortality after TAVI [8]. Unlike other recent studies evaluating the early outcome after TA-TAVI [9] we did not compare different transcatheter valve systems but focused on the impact of patient related parameters.


Characteristics of the study and main objective

This is a single center cohort study (University Heart Center Rostock, Germany). The aim of the current study was to isolate patient- and approach-related predictors of adverse procedural outcome in terms of limited device success and early mortality following transapical TAVI.

Study population

Sixty consecutive patients treated by a TA-TAVI procedure after heart team consent on a high surgical risk (EuroScorelog ≥ 20 or porcelain aorta) between January 2010 and November 2011were included into the analysis.

Data collection and endpoints

All procedural and clinical data as well as data on 30-day outcome were collected from the interventional and/or clinical protocols as well as the discharge letters and the letters from the hospitals/physicians responsible for the secondary care. In order to analyze for both, limited device success and an unfavorable early clinical outcome of TA-TAVI, three endpoints were defined: More than mild postoperative paravalvular leak (PVL), postoperative mean transvalvular gradient >14 mmHg assessed by transthoracic echocardiography and a composite endpoint of 30-day mortality, stroke and myocardial infarction. Two independent investigators quantified parameters describing the intracardiac anatomy by evaluation of preoperative multi-slice computed tomography (MSCT) examinations.


All data were stored and analyzed using the IBM® SPSS® Statistics 22.0. Data are expressed as frequencies/proportions (%) for categorical variables or as mean ± standard deviation (SD) for continuous variables. A logistic regression model was applied for the analysis to assess the independence of procedural outcome and early clinical outcome from predictors. Odds ratios (OR’s) and the respective 95% confidence intervals (CI’s) were calculated. The potential predictor variables for the primary univariate analysis were patient related, such as: male gender (vs. female), age ≥ 80 years (vs. <80 years), BMI ≥ 30 kg/m2 (vs. <30 kg/m2), obstructive pulmonary disease (COPD) (vs. none), presence of a chronic kidney disease ≥ stage 2 (glomerular filtration rate <60 ml/min/1.73 m2) (vs. none orstroke (vs. none), history of malignant tumor (vs. none), prior cardiac surgery (vs. none), frailty (according to the Johns Hopkins Frailty Criteria) (vs. none), preoperative NT-proBNP level <400 pg/ml (vs. ≥ 400 pg/ml), as well as parameters describing the valvular pathology and approach-related intracardiac anatomy such as more than moderate calcification of the ascending aorta (based on a semi-quantitative scoring of preoperative CT images) (vs. none or mild), diameter of the intraventricular septum ≥17 mm (vs. <17 mm) , LVOT-aorta angle <120° (vs. ≥ 120°) and left ventricular enddiastolic diameter ≥ 55mm (vs. <55 mm).

Statistical significance was assumed for p <0.05. Predictor candidates showing p <0.25 by univariate analysis entered a subsequent multivariate regression model, and the adjusted ORs (ORadj) with the respective p-values and CIs were calculated. Those candidates are referred to as predictors here, if they at least double (ORadj >2) or halve (ORadj <0.5) the risk, respectively.


Baseline characteristics

All 60 patients were treated using the Edwards Sapien device. Baseline characteristics, as wells as patient-and approach-related risk factors are summarized in Table 1. Baseline data confirm the presence of a surgical high-risk cohort.

  Frequency (proportion %)/mean ± SD
Sex category male 30 (50%)
Age 77.7 ± 6.3
More than mild aortic calcification 22 (43.1%)
Intraventricular septum ≥ 1.7cm 35 (68.6%)
LVEDD (mm) 51.1 ± 9.5
LVOT-aorta angle (°) 132.2 ± 10.2
NTproBNP 7427.7 ± 11724.4
COPD 19 (31.7%)
Prior cardiac surgery 9 (15%)
Chronic kideny disease >stage 2 33 (55%)
Prior malignancy 8 (13.3%)
Prior stroke 11 (18.3%)
BMI >=30 kg/m2 20 (33.3%)
Frailty 20 (33.3%)

Table 1: Baseline characteristics of the patient cohort (N=60). Baseline characteristics of the study population. BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; LVEDD: Left Ventricular End Diastolic Diameter; LVOT: Left Ventricular Outflow Tract; SD: Standard Deviation.

Predictors of more than mild paravalvular leak

The observed rate of more than mild paravalvular leak in the study cohort was 3.7%. Univariate logistic regression analysis was performed to assess the influence of patient and approach-related risk factors with more than mild postoperative paravalvular leak. The results of the univariate and subsequent multivariate analyses are displayed in Table 2. The presence of a BMI ≥ 30 (OR 2.57 95% CI 0.69-9.52; p=0.157) was found to double the risk in terms of postoperative PVL.

  Univariate model Multivariate model
Potential predictor variable OR 95% CI p-value ORadjusted 95% CI p-value
BMI ≥ 30 kg/m2 2.76 0.76-10.1 0.124 2.57 0.69-9.52 0.157
Chronic kidney disease > stage 2 1.95 0.64-5.95 0.241 1.77 0.57-5.55 0.327
More than moderate aortic calcification 1.72 0.53-5.66 0.369      
Intraventricular Septum ≥ 17mm 1.58 0.47-5.35 0.459      
LVEDD > 55 mm 1.42 0.37-5.47 0.613      
Prior Cardiac Surgery 1.33 0.31-6.03 0.709      
COPD 1.25 0.38-4.12 0.714      
Frailty 1.23 0.39-3.85 0.721      
Prior Malignancy 1.31 0.22-7.87 0.768      
Male Sex 1.17 0.39-3.49 0.78      
Pre OP NTproBNP <400 pg/ml 1.38 0.12-16.3 0.798      
Age ≥ 80 years 1.09 0.36-3.27 0.876      
LVOT-aortic angle<120° 1.1 0.25-4.76 0.898      
Prior Stroke 1.06 0.26-4.31 0.936      

Table 2: Predictors of more than mild paravalvular leak (Logistic Regression Analysis). BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; LVEDD: Left Ventricular End Diastolic Diameter; LVOT: Left Ventricular Outflow Tract; SD: Standard Deviation.

Predictors of an unfavorable postoperative gradient

The observed mean postoperative transvalvular gradient was 12.1 ± 5.5 mmHg. Regression analysis suggests associations of two patient and approach-related risk factors with unfavorable (mean gradient >14 mmHg) postoperative gradients (Table 3). A BMI ≥ 30 (OR 2.32 95% CI 0.57-9.45, p=0.242), as well as a preoperative NT-proBNP level <400 pg/ml (OR 5.15 95% CI 0.32-81.9, p=0.246) predicted a trend towards a mean postoperative gradient beyond 14 mmHg, however without reaching statistical significance. In contrast male gender (OR 0.50 95% CI 0.13-1.91, p=0.309) and the presence of COPD (OR 0.45, 95% CI 0.10-2-13, p=0.315) were found to be associated with a decreased risk of elevated postoperative gradients.

  Univariate model Multivariate model
Potential predictor variable OR 95%-CI p-value OR 95%-CI p-value
Male Sex 2.64 0.75-9.31 0.131 2.01 0.52-7.76 0.309
Pre OP NTproBNP <400 pg/ml 4.77 0.40-57.31 0.218 5.15 0.32-81.9 0.246
BMI ≥ 30 kg/m2 2.23 0.6-8.28 0.231 2.32 0.57-9.45 0.242
Intraventricular Septum ≥ 17m 2.22 0.51-9.79 0.291      
LVEDD ≥ 55 mm 2.05 0.51-8.12 0.309      
Chronic kideny disease > stage 2 1.75 0.52-5.83 0.365      
Prior Stroke 1.87 0.43-8.19 0.408      
Frailty 1.56 0.46-5.29 0.479      
Prior Malignancy 2.07 0.21-20.19 0.532      
LVOT-aortic angle <120° 1.38 0.24-7.93 0.722      
Age ≥ 80 years 1.21 0.36-4.02 0.756      
More than moderate aortic calcification 1.22 0.32-4.63 0.766      

Table 3: Predictors of unfavorable post-procedural transvalvular gradients (Logistic regression analysis). BMI: Body Mass Index; LVEDD: Left Ventricular End Diastolic Diameter; LVOT: Left Ventricular Outflow Tract; SD: Standard Deviation.

Predictors of 30-day mortality, stroke and myocardial infarction

The total event rate in terms of the composite endpoint (30-day mortality, stroke and myocardial infarction) was 13.6%. Patient and approach-related predictors for poor early postoperative outcome according to the defined composite endpoint were investigated (Table 4). Of all analyzed parameters only male gender (OR 5.88 95% CI 0.50-69.6, p=0.160) as well as a steep LVOT-aorta angle <120° (OR 6.65 95% CI 0.93-47.4, p=0.059) were found to influence the risk for an unfavorable early postoperative outcome, however with only the latter one coming close to statistical significance.

  Univariate model Multivariate model
Potential predictor variables OR 95%-CI p-value OR 95%-CI p-value
Male Sex 9.23 1.06-80.60 0.044 5.88 0.50-69.63 0.16
LVOT aortic angle < 120° 5.29 0.88-31.74 0.069 6.65 0.93-47.36 0.059
Frailty 4.16 0.47-36.43 0.198 1.65 0.12-22.6 0.706
COPD 2.4 0.53-10.88 0.256      
Intraventricular Septum ≥ 17mm 2.33 0.25-21.89 0.458      
Prior Stroke 1.56 0.27-9.00 0.622      
Chronic kideny disease > stage 2 1.48 0.32-6.87 0.615      
More than moderate aortic calcification 1.52 0.25-9.19 0.648      
Prior Cardiac Surgery 1.3 0.14-12.08 0.816      
BMI ≥ 30 kg/m2 1.2 0.26-5.63 0.817      
Age ≥ 80 years 1.31 0.25-5.63 0.877      
Prior Malignancy 1.11 0.12-10.48 0.925      

Table 4: Predictors of the composite outcome; 30-day mortality. stroke. myocardial infarction (Logistic Regression analysis). BMI: Body Mass Index; LVEDD: Left Ventricular End Diastolic Diameter; LVOT: Left Ventricular Outflow Tract; SD: Standard Deviation.


After several years of transcatheter aortic valve therapy there is growing evidence that standardized risk scores, for example the logistic EuroScore and the STS-score-utilized to evaluate patients prior an aortic valve procedure are limited in terms of predicting the early procedural and clinical outcome following TAVI [10].

The current study provides evidence, that specific approach-related outcome predictors, such as parameters reflecting the intracardiac anatomy, might be able to predict procedural and early clinical outcome following TA-TAVI more accurately than risk scores standardized for conventional AVR alone.

The EuroScore failed to predict outcome following TAVI in the SOURCE Registry [11]. Additionally, the EuroScore overestimates the periprocedural risk even for conventional surgery [12]. Although the STS score has been shown to outperform the logistic EuroScore as well as the new EuroScore 2 in terms of predicting long and short-term survival following TAVI [13,14], it recently failed to predict in 30-day mortality after TAVI [10]. Altogether, there is currently no scoring system available predicting specifically the procedural outcome and early survival following TAVI and patient selection still relies on the application risk scores standardized for conventional AVR.

However in the modern era of aortic valve therapy patient evaluation prior TAVI should specifically predict clinical outcome and the chance of device success according to the VARC criteria [15] -i.e. excellent valve performance with no paravalvular leak and low gradients - in every single patient. This seems of outstanding importance, especially when evaluating patients exhibiting a “borderline” risk, which could be candidates for either a transcatheter or a conventional procedure.

The current study was designed to provide evidence, that specific patient and approach-related parameters are capable to predict the early outcome and valve performance following TA-TAVI.

Although obtained from a rather small cohort, our results are applicable to everyday clinical decisions, as they derive from a real-life scenario, utilizing the most common valve type (Edwards Sapien) for the TA approach.

From all analyzed parameters especially a steep LVOT-aorta angle, reflecting a rather difficult intracardiac anatomy for the TA approach, was found to predict unfavorable early clinical outcome. Interestingly, for example preoperative frailty did not predict early mortality in a comparable extent. This finding is in line with the underlying hypothesis that specific approach-related parameters might outperform a rather global risk categorization in terms of outcome prediction after TA-TAVI. Besides the LVOT-aorta angle, obviously representing a key anatomic parameter in TA procedures, for example the calcification of the device landing zone has been shown to predict unfavorable procedural outcome in terms of paravalvular leak [16] and postoperative pacemaker dependency [17]. Similarly, the total aortic calcification burden has been recently described as an integrative predictor of mortality after TAVI [8]. However, since the importance of these variables has already been demonstrated, we did not include them in the current analysis.

Another potentially relevant patient related parameter for outcome prediction after TA-TAVI elaborated by our study is serious obesity reflected by the BMI. Limited device success following a TA procedure characterized by a more than mild PVL or elevated postoperative gradients was predicted by serious obesity, obviously representing a possibly complicating factor of a TA approach. However, as others [18], we did not find an association of obesity and worse clinical outcome after TA TAVI.

The association between a low preoperative NT-proBNP level and elevated postoperative gradients is not so obvious. However, it is conceivable to estimate that patient exhibiting a rather good preoperative LV function reflected by a low NT-proBNP level might be more prone to generate higher postoperative gradients after TAVI. On the other hand plasma B-type natriuretic peptide has been identified previously as a predictor of all-cause mortality after TAVI [19].

Accordingly, the demonstrated association of male gender and the presence of COPD with a decreased risk of elevated postoperative gradients cannot be explained definitely from the current data, although it seems at least plausible to hypothesize that both patient subgroups are probably more likely to receive a larger prosthesis thereby decreasing the risk of elevated post-procedural gradients.

After decades of experience the integration of approach-related parameters represents a mainstay of patient evaluation for conventional cardiac surgery. The growing experience in transcatheter aortic valve therapy should lead to the integration of similar parameters also into the evaluation process for TAVI procedures. This kind of integration should support the further development of new risk scores, such as the recently proposed TAVI2-SCORe [20] designed specifically for the evaluation of candidate patients for TAVI.

We strongly believe, that the effort of implementing dedicated patient- and approach-related parameters within the algorithm of patient evaluation prior TAVI procedures is worthwhile, since it has become increasingly clear that the common calculation of surgical risk alone is unsatisfactory for an elaborated patient and approach selection prior TAVI.

In conclusion the current analysis provides additional evidence that the integration of specific patient- and approach-related parameters such as the LVOT-aorta angle into the preoperative patient evaluation would most likely improve outcome prediction of patients undergoing TAVI procedures. However, the analysis of larger patient cohorts is mandatory in order to consolidate this preliminary evidence.


This is a pilot study from an ongoing single-center TAVI registry, including a cohort of 60 patients. The study was designed with the objective to provide sufficient preliminary evidence in order to prepare the ground for subsequent larger studies validating specific predictors. The focus here was on descriptive statistics and estimations, and our study results may rather indicate whether an impact of the investigated predictor candidates is to be expected or not. Since pilot studies are usually underpowered, all results of no statistical significance are to be interpreted in a strictly explorative way.

Conflict of Interest

Author declare no conflict of interest.


  1. Charlson E, Legedza AT, Hamel MB (2006) Decision-making and outcomes in severe symptomatic aortic stenosis. J Heart Valve Dis 15: 312-321.
  2. Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, et al. (2004) Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol 43: 698-703.
  3. Agnihotri A; American Association for Thoracic Surgery; American College of Cardiology Foundation; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons (2012) 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: executive summary. J Thorac Cardiovasc Surg 144: 534-537.
  4. Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, et al. (2012) Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 366: 1705-1715.
  5. Anderson RP (1994) First publications from the Society of Thoracic Surgeons National Database. Ann Thorac Surg 57: 6-7.
  6. Roques F, Michel P, Goldstone AR, Nashef SA (2003) The logistic EuroSCORE. Eur Heart J 24: 881-882.
  7. Biancari F, Rosato S, D'Errigo P, Ranucci M, Onorati F, et al. (2016) Immediate and Intermediate Outcome After Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement. Am J Cardiol 117: 245-251.
  8. Harbaoui B, Montoy M, Charles P, Boussel L, Liebgott H, et al. (2016) Aorta calcification burden: Towards an integrative predictor of cardiac outcome after transcatheter aortic valve implantation. Atherosclerosis 246: 161-168.
  9. Kempfert J, Meyer A, Kim WK, Van Linden A, Arsalan M, et al. (2016) Comparison of two valve systems for transapical aortic valve implantation: a propensity score-matched analysis
  10. Gogbashian A, Sedrakyan A, Treasure T (2004) EuroSCORE: a systematic review of international performance. Eur J Cardiothorac Surg 25: 695-700.
  11. Hemmann K, Sirotina M, De Rosa S, Ehrlich JR, Fox H, et al. (2013) The STS score is the strongest predictor of long-term survival following transcatheter aortic valve implantation, whereas access route (transapical versus transfemoral) has no predictive value beyond the periprocedural phase. Interact Cardiovasc Thorac Surg 17: 359-364.
  12. Haensig M, Holzhey DM, Borger MA, Schuler G, Shi W, et al. (2013) Is the new EuroSCORE II a better predictor for transapical aortic valve implantation? Eur J Cardiothorac Surg 44: 302-308.
  13. Mihara H, Shibayama K, Harada K, Berdejo J, Itabashi Y, et al. (2014) Device landing zone calcification predicts significant paravalvular regurgitation after transcatheter aortic valve replacement: a real time three-dimensional transesophageal echocardiography study. Echocardiography 31: E142-144.
  14. Latsios G, Gerckens U, Buellesfeld L, Mueller R, John D, et al. (2010) "Device landing zone" calcification, assessed by MSCT, as a predictive factor for pacemaker implantation after TAVI. Catheter Cardiovasc Interv 76: 431-439.
  15. Takagi H, Umemoto T; Group for the Alice (All-Literature Investigation of Cardiovascular Evidence) (2016) "Obesity paradox" in transcatheter aortic valve implantation. J Cardiovasc Surg (Torino) .
  16. Debonnaire P, Fusini L, Wolterbeek R, Kamperidis V, van Rosendael P, et al. (2015) Value of the "TAVI2-SCORe" versus surgical risk scores for prediction of one year mortality in 511 patients who underwent transcatheter aortic valve implantation. Am J Cardiol 115: 234-242.
Citation: Donndorf P, Fries A, Glass A, Steinhoff G, Kaminski A (2016) Predicting Device Success and Early Clinical Outcome after Transapical Aortic Valve Implantation. J Clin Trials 6:259.

Copyright: © 2016 Donndorf P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.